Triplex formation at the rat neu oncogene promoter☆
References (27)
- et al.
Triplex formation prevents Spl binding to the dihydrofolatc reductase promoter
J. Biol. Chem.
(1992) - et al.
Structure and applications of intermolecular DNA triplexes
Am. J. Med. Sci.
(1992) Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides
Eur. J. Cancer
(1991)- et al.
Inhibition of transcription of HIV-1 in infected human cells by oligodeoxynucleotides designed to form DNA triple helices
J. Biol. Chem.
(1992) - et al.
The retinoblastoma gene product suppresses neu oncogenc-induced transformation via transcriptional repression of neu∗
J. Biol. Chem.
(1992) - et al.
Increased tyrosine kinase activity associated with the protein encoded by the activated neu oncogene
- et al.
Second structural motif for recognition of DNA by oligonucleotide-directed triple-helix formation
Science
(1991) - et al.
Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro
Science
(1988) - et al.
Triplex forming oligonucleotide reagents: rationalization of DNA site selectivity and application in a pharmaceutical context
- et al.
Binding of triple helix forming oligonucleotides to sites in gene promoters
Biochemistry
(1991)
Triplex formation inhibits HER2/neu transcription in vitro
J. Clin. Invest.
(1993)
Cloning by recognition site screening of two novel GT box binding proteins: a family of Spl related genes
Nucleic Acids Res.
(1992)
M olecular cloning of the neu gene: absence of gross structural alteration in oncogenic alleles
Cited by (10)
Nonviral approaches for cancer gene therapy
2003, Pharmaceutical Gene Delivery SystemsTriplex-forming oligonucleotides: Principles and applications
2002, Quarterly Reviews of BiophysicsHuman glioma cells transformed by IGF-I triple helix technology show immune and apoptotic characteristics determining cell selection for gene therapy of glioblastoma
2001, Journal of Clinical Pathology - Molecular PathologyIGF-I triple helix strategy in hepatoma treatment
2001, Hepato-GastroenterologyDiscrimination of a single base change in a ribozyme using the gene for dihydrofolate reductase as a selective marker in Escherichia coli
1997, Proceedings of the National Academy of Sciences of the United States of America
- ☆
Presented at the Palo Alto Institute of Molecular Medicine Symposium on “Pharmaceutical Design: Anti-Sense, Triple Helix, Nucleic Acid-Binding Drugs”, January 31-February 1, 1994; Hyatt Rickeys, Palo Alto, CA, USA.
Copyright © 1994 Published by Elsevier B.V.